A recent landmark phase 2b clinical trial demonstrated the clinical benefit of pan-PPARα/γ/δ agonist lanifibranor in non-alcoholic steatohepatitis to slow the progression of fibrosis (NCT03008070) [124]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.